KURE is trading at $18.57, up 6.35%, amid stronger broad-market sentiment, though no KURE-specific catalyst was identified. - Major U.S. indexes were up more than 1.7% as election uncertainty eased. - KURE holds Chinese healthcare companies across biotechnology, pharmaceuticals, medical devices, and related areas. Broad risk appetite may be supporting the fund, but this does not establish a direct cause. - Trading is live; volume information was not provided.